Overall, IL-7 is expected to broaden the amplitude of the response against malignant cells that escape the immune system by mutation and immuno-editing and should help metastatic cancer patients to restore TCR repertoire diversity for improved anti-tumor immune response. The gene discussed is IL7; the disease is neoplasm.